ELAN logo

Elanco Animal Health Incorporated Stock Price

NYSE:ELAN Community·US$10.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

ELAN Share Price Performance

US$21.09
7.11 (50.86%)
US$21.91
Fair Value
US$21.09
7.11 (50.86%)
3.7% undervalued intrinsic discount
US$21.91
Fair Value
Price US$21.09
AnalystConsensusTarget US$21.91
AnalystLowTarget US$12.00
AnalystHighTarget US$19.15

ELAN Community Narratives

AnalystConsensusTarget·
Fair Value US$21.91 3.7% undervalued intrinsic discount

Upcoming Launches And Market Developments Will Shape Earnings Expectations This Year

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AnalystLowTarget·
Fair Value US$14.39 46.6% overvalued intrinsic discount

Mounting Debt And Patent Risks Will Crush Future Net Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value US$18 17.2% overvalued intrinsic discount

Global Animal Protein Demand Will Drive Breakthroughs Amid Regulatory Risks

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$14.39
46.6% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
3.42% p.a.
Profit Margin
1.94%
Future PE
91.76x
Share price in 2028
US$17.5
US$18
17.2% overvalued intrinsic discount
Revenue growth
5.29% p.a.
Profit Margin
4.07%
Future PE
51.84x
Share price in 2028
US$21.66

Snowflake Analysis

Undervalued with moderate growth potential.

3 Risks
3 Rewards

Elanco Animal Health Incorporated Key Details

US$4.6b

Revenue

US$2.1b

Cost of Revenue

US$2.5b

Gross Profit

US$2.5b

Other Expenses

US$36.0m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.072
54.96%
0.78%
55.8%
View Full Analysis

About ELAN

Founded
1954
Employees
9225
CEO
Jeffrey Simmons
WebsiteView website
www.elanco.com

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Recent ELAN News & Updates

Recent updates

No updates